<DOC>
	<DOCNO>NCT01561898</DOCNO>
	<brief_summary>The purpose study assess safety JNS007ER 3-12 mg daily patient schizophrenia long term period .</brief_summary>
	<brief_title>A Long-Term Study JNS007ER Patients With Schizophrenia</brief_title>
	<detailed_description>This 48-week , multicenter , open-label ( people know identity intervention ) , non-controlled , arbitrary-dose study . The patient include study participate precede double-blind ( neither physician patient know treatment patient receives ) comparative trial ( study JNS007ER-JPN-S31 ) JNS007ER complete study , remain study evaluation 2 week discontinue study insufficient treatment efficacy . The study assess safety JNS007ER clinical recommend dose range long term treatment . The dosage start 6 mg/day , increase decreased 3 mg time depend patient 's symptom within range 3 mg/day 12 mg/day . For dose adjustment , investigator evaluate psychiatric symptom define dose change . Detailed Description : Extended description protocol , include technical information ( compare Brief Summary ) desire . Do include entire protocol ; duplicate information record data element , eligibility criterion outcome measure .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Patients diagnose schizophrenia Patients give consent write participate study Patients untreated antipsychotic within 28 day screen test Patients complete Study JNS007ERJPNS31 , continue study least evaluation 2 week subsequently discontinue study due insufficient efficacy Patients participate Study JNS007ERJPNS31 whose ratio treatment evaluation 2 week â‰¥75 % Patients diagnosed mental disease schizophrenia A total PANSS score &gt; 120 baseline Substancerelated disorder Parkinson 's disease complication Current past history convulsive disease epilepsy Current past history cerebrovascular accident Diabetes mellitus Significant hepatic renal impairment Significant cardiovascular disorder Abnormal result hematological examination , blood chemistry test urinalysis screen Pregnant woman , breastfeed mother , patient wish pregnancy study period whose pregnancy test screen positive Contraindications risperidone product Patients discontinue Study JNS007ERJPNS31 due adverse event relate underlying disease Patients judge inadequate investigator participate study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>JNS007ER</keyword>
	<keyword>Paliperidone extended-release</keyword>
</DOC>